Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-bromopalmitate (2-BP) is a synthetic, non-metabolizable analogue of palmitic acid that acts as a broad-spectrum irreversible inhibitor of protein S-palmitoylation, a reversible post-translational lipid modification of proteins. It is widely used as a biochemical tool in research to inhibit palmitoylation-dependent cellular processes, including signal transduction, protein trafficking, and membrane association of several proteins. 2-bromopalmitate has shown activity in cell signaling and neuroscience studies, particularly for modulating the function of palmitoylated signaling proteins. The compound is not approved for therapeutic or diagnostic human use and is strictly for laboratory research applications[4][6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-bromopalmitate.